The FDA approved Roche's ocrelizumab for the treatment of relapsing and primary progressive multiple sclerosis (PPMS), wrapping up a 40-year development history for the anti-CD20 monoclonal antibody (mAb). This is the first drug approval for PPMS, a form of the neurodegenerative disease that

中文翻译：

---

FDA批准首个用于原发性进行性多发性硬化症的药物

FDA批准罗氏ocrelizumab用于治疗复发性和原发性进行性多发性硬化症（PPMS），总结了抗CD20单克隆抗体（mAb）已有40年的开发历史。这是PPMS的首个药物批准，PPMS是一种神经退行性疾病，